Toggle Main Menu Toggle Search

Open Access padlockePrints

Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma

Lookup NU author(s): Dr Lindi Chen, Dr Yan Zhao, Dr Gail Halliday, Philip Berry, Professor Herbie Newell, Professor John Lunec, Professor Deborah Tweddle

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Background:A frequent mechanism of acquired multidrug resistance in human cancers is overexpression of ATP-binding cassette transporters such as the Multi-Drug Resistance Protein 1 (MDR-1). Nutlin-3, an MDM2-p53 antagonist, has previously been reported to be a competitive MDR-1 inhibitor.Methods:This study assessed whether the structurally diverse MDM2-p53 antagonists, MI-63, NDD0005, and RG7388 are also able to modulate MDR-1 function, particularly in p53 mutant neuroblastoma cells, using XTT-based cell viability assays, western blotting, and liquid chromatography-mass spectrometry analysis.Results:Verapamil and the MDM2-p53 antagonists potentiated vincristine-mediated growth inhibition in a concentration-dependent manner when used in combination with high MDR-1-expressing p53 mutant neuroblastoma cell lines at concentrations that did not affect the viability of cells when given alone. Liquid chromatography-mass spectrometry analyses showed that verapamil, Nutlin-3, MI-63 and NDD0005, but not RG7388, led to increased intracellular levels of vincristine in high MDR-1-expressing cell lines.Conclusions:These results show that in addition to Nutlin-3, other structurally unrelated MDM2-p53 antagonists can also act as MDR-1 inhibitors and reverse MDR-1-mediated multidrug resistance in neuroblastoma cell lines in a p53-independent manner. These findings are important for future clinical trial design with MDM2-p53 antagonists when used in combination with agents that are MDR-1 substrates.British Journal of Cancer advance online publication, 12 June 2014; doi:10.1038/bjc.2014.325 www.bjcancer.com.


Publication metadata

Author(s): Chen L, Zhao Y, Halliday GC, Berry P, Rousseau RF, Middleton SA, Nichols GL, Del Bello F, Piergentili A, Newell DR, Lunec J, Tweddle DA

Publication type: Article

Publication status: Published

Journal: British Journal of Cancer

Year: 2014

Print publication date: 12/06/2014

ISSN (print): 0007-0920

ISSN (electronic): 1532-1827

Publisher: Nature Publishing Group

URL: http://dx.doi.org/10.1038/bjc.2014.325

DOI: 10.1038/bjc.2014.325

PubMed id: 24921920


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share